AYUSH Ministry is endangering people, jeopardising Ayurveda with feeble responses to Patanjali's Coronil stunt and COVID-19

After a public launch of an alleged “cure” for COVID-19, Patanjali Ayurved’s marketing stunt with ‘Coronil’ has effectively backfired. The two COVID-19 treatments that the Ayurveda and FMCG giant launched last week were publicised prematurely and with no clinical data to prove they were even effective, let alone safe.

The news was met with harsh criticism on social media, dragged through the dirt on Twitter within minutes of making headlines. Hours later, and well after the controversy had erupted, the Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) responded to the news with a stern statement urging Patanjali to stop advertising their product till its claims were verified by the ministry and the product, given approval.

“If you’ve seen the trial report that Patanjali has sent out, it excludes everybody below 10 years and above 59 years, people with diabetes, hypertension, respiratory diseases, cancer,” Dr Om Srivastava, Visiting Professor (Infectious Diseases) and Director of the Infectious Diseases Department at Jaslok Hospital, Mumbai, says.

“To people who are asymptomatic in the mild form of the disease, the recovery rate is between 95 and 97 percent already. So what are you really achieving?”

Moreover, some practitioners are confused as to how Patanjali could have named, developed, and advertised a product without receiving approvals from the AYUSH ministry in the first place.

“If you look at the Pharmacopoeial Medicines R&R page which is applicable to homeopathy and any form of medication under AYUSH for that matter, the medicine requires an approval before which you can’t name a medicine. And till that happens, they cannot issue a public notice claiming the drug,” says Dr Radhika Tonsey, a homoeopathy physician who also consults at the Jerbai Wadia Hospital for Children and Research Centre in Mumbai.

The AYUSH ministry chief has since denied giving Patanjali clearance to sell or advertise coronil, in an interview with Times Now.

Patanjali’s lax ethical standards is old news

In the past, Patanjali has been reprimanded twice for flouting rules. The first, for its Atta instant noodles, which it launched in 2016 without a mandatory approval from the Food Safety and Standards Authority of India (FSSAI). The second was the sale of its amla juice, which was suspended after the Ministry of Defence's canteen stores department after it was found “unfit for consumption” in an adverse state-laboratory test on the product.

Considering the impressive spread of over 45 kinds of cosmetics products, 30 types of food products, and hundreds of medical formulations under the Patanjali Ayurved umbrella, the lack of a mention anywhere in the company’s website of a certificate of safety, ethics or good manufacturing is surprising.

 

Patanjali’s ambition train hasn’t quite run out of steam yet. In 2019, a series of investigative reports by Business Standard reveal that the company acquired 400 acres of forested, hilly common land in kot, in the Aravalli region by bending norms. In June 2019, the Maharashtra government handed over another 400-acre-plot of land to Patanjali reserved for Bharat Heavy Electricals Limited (BHEL), in Latur.

In 2020, the Uttar Pradesh government offered the company a land subsidy to set up a proposed food park in Greater Noida. This, despite reports of the company’s unplanned expansion, poor supply chain, inconsistent product quality and business practices, combined with an economic slowdown in 2019 having hurt its revenues, as per a report in The Print.

'No ethics, no medicine'

Patanjali Ayurved has undeniably made a range of products easily accessible to the masses. It’s Aloe Vera gel for instance, experts say, has helped a lot of people overcome acne, skin allergies, and other dermatological problems. It also has raving ratings and reviews on Amazon.in.

And while some of their products have empirical evidence to stand on, can the same be said for all 2,500+ products made available at jaw-droppingly affordable prices countrywide on their website?

It’s Amla Churna, priced at Rs 24 for a 100g-bottle, has the listed ingredients “Amla” and the benefits “Boosts digestion and reduces constipation, cures eye problem, reduces hair fall, cures cold, has antioxidant properties.” Only two of the six surprisingly clear claims made and displayed are verifiable as per research studies carried out in the past. It doesn’t help that Patanjali’s formulations for its many thousands of products are not in the public domain, leaving the decision entirely onto consumers to take on an implied degree of risk.

Tonsey, says that Patanjali products have helped many consider Ayurveda as an accessible option for the first time.

“But for me, that’s where it ends. Because the ethics at every stage are questionable...and when it comes to medicine, no matter what the system is, no ethics means no medicine,” she said.

Systems around alternative medicine are far from developed

Alternative medicine has suffered a great deal more pressure to compete for the faith and attention of the public. More tangibly, the science of alternative medicine is seriously stunted by research funding – in that it receives a dearth of it. This is the same case in many countries worldwide, and not just India.

Allopathy, on the other hand, has a track record to show for its growth and development over the years. It is considered more reliable, owing to its tried-and-tested format, with a potential drug today having to pass several hoops and exchange many hands in safety and efficacy tests before making it to consumers. These systems around allopathy have also expanded and evolved to meet rising demand and address a wide range of medical needs.

Conventional medicine in India is governed and supervised by the Drug Controller General of India and has a competitive manufacturing market with local and international players. It also has a powerful body setting standards for drugs and medical devices across the country [the Central Drugs Standard Control Organisation (CDSCO)]. All three aim to serve the diverse and dynamic Indian pharmaceutical market in their own way.

In stark contrast, the research, systems, and regulations governing alternative medicines in India are relatively rudimentary. The Ministry of AYUSH is the foremost authority in India that both governs and regulates the five distinct disciplines under its domain. Directly under the AYUSH ministry’s wing are five research councils, two regulatory bodies for education and practice (with a separate body for homoeopathy), three testing and research laboratories, and eleven educational institutions.

Apart from these, the ministry bands together Task Forces, as and when needed for special circumstances. Most recently, an interdisciplinary Task Force was formed under AYUSH to look into suitable research avenues in addressing COVID-19 with AYUSH treatments. This was announced after the backlash it received for its controversial advisory dated 6 March, which listed many general preventive medicines for boosting immunity in light of the COVID-19 pandemic.

Questionable medical advice from AYUSH without supporting research

In a COVID-19 advisory published on 6 March, AYUSH made a variety of recommendations for “symptomatic relief” from COVID-19. These, as per the report, are based on “classical texts”, of which there are several, and “scientific literature” – which is universally and traditionally used in research with citations, and not as an unlisted bibliography at the end of the report.

The lack of sources cited for the specific recommendations made in the advisory, and other guidelines for COVID-19 treatment published around the same time, has left practitioners of alternative medicine either hunting for valid proof themselves, or flouting further unsupported claims about these medicines in the news.

Since the advisories were published, Camphora 1M and Arsenic album 30 have reportedly been flying off shelves, being distributed to police officers, and even preemptively popped by the general public without seeking the advice of a medical professional.

Allopathic medicines that are being considered as treatments for COVID-19 are being subjected to rigorous clinical trials to test their efficiency against the SARS-CoV-2 virus that causes COVID-19. Some candidates have even been shown to work in specific cases, in preliminary clinical settings. For instance, the inexpensive steroid drug dexamethasone, which, too, has reportedly been stockpiled without a valid prescription, could have potentially dangerous consequences.

There is not a single published study or trial, specific to the coronavirus, that proves arsenic alba, or any other compound for that matter, is an effective remedy to prevent infection. And yet, the advisory recommended a sizable list of “preventives and prophylaxis” for COVID-19, including Arsenic album 30 and camphora.

Some Unani medicines are even listed with unclear instructions for how to use them; phrases like “boil it till it remains half- filter it” appear to be unedited after a language translation to English.

The real dangers of AYUSH’s messaging, without follow-through

AYUSH’s approach of prescribing “preventive” medicine for COVID-19 brings out the plausible loophole that Patanjali themselves have openly flouted. The huge gaps in acceptable research standards for alternative medicine in India, and regulation of AYUSH practice in accordance with guidelines, have left considerable room for error and malpractice.

In an interview with Infinity Foundation, Dr Dayananda R D from Prakruthi Ayurveda Prathishtana in Mysore, explains that the equivalent of vaccination for prevention in Ayurveda is not easy, but possible with personalised advice from an Ayurvedic doctor.

“To improve one’s immune defense...(Ayurveda) prescribes certain improvements through food, lifestyle and certain medicines, to be taken with regulations. To make it generalised is a slightly difficult task, and so the person can go to a doctor and personalise it according to their desa (place of birth), the disease, and their prakriti (nature),” Dayananda says.

This important condition is not highlighted by AYUSH in any of their advisories, making for incomplete advice. The potential dangers of popping allopathic medicines may very well be greater than their plant-based counterparts. But the combination of subjective medical advice and a lack of regulation in AYUSH drugs as it stands today, leaves room for improper dosage, interpretation and potential misuse.

Those taking AYUSH-recommended medicines are likely to develop a false bravado vis-à-vis the extent to which they’re protected from infections. With medicine, particularly ones that are not prescribed by a medical professional and given out as general advice, the potential for misuse needs to be considered with added caution.

“Camphora is given in a state of collapse...when there are so many symptoms similar to a state of collapse, like sweating profusely, or not responding, semi-conscious or comatose,” Tonsey says. “If something happens to anybody, who is going to take responsibility for it?”

Half-baked recommendations in a pandemic could also potentially worsen the load on the already-burdened public healthcare system, and ongoing efforts to ensure the pandemic doesn’t spread further. Coming at a time when the public has been advised to be cautious and alert for symptoms of an infection that we are only now beginning to understand, it is arguably unacceptable.

The AYUSH ministry’s attempt to quell publicity around Patanjali’s 'Coronil' was about as effective as their general approach to misinformation going around about remedies effective to prevent COVID-19 – not at all. The ministry has also not followed through on its a href="https://ift.tt/3eEzebs" target="_blank">own advice, as of April 2020, to “take necessary action against” Patanjali for “contravening the relevant legal provisions” they outlined for advertising unapproved AYUSH products.

After The New York Times published a report by The Associated Press on 17 April titled “Some People Turn to Herbal Medicine for Virus without Proof,” the Press Information Bureau’s Director-General responded to the NYT editor (instead of AP's Editor) with a letter pointing out the author’s “unprofessional attempts to revive clichéd stereotypes” and “assertions...not aligned to the facts of the matter.”

Nonetheless, the PIB’s effort to defend the government’s and AYUSH’s debatable actions is admirable. It still strays from the larger threat to people who swear by Ayurveda and homoeopathy, and spills over to the development of these disciplines themselves, which cannot afford to be compromised any further than it already is.

Ayurveda and homoeopathy work very differently than conventional medicines do

Ayurveda and homoeopathy are arguably two of the biggest pseudoscientific* practices under the AYUSH umbrella. Started in 2014, the Ministry was set up with the goal of "optimal development and propagation" of the systems of health care under its domain, through education, research and propagation of indigenous alternative medicine systems.

[*pseudoscientific–falsely or mistakenly claimed or regarded as being based on a scientific method]

Homoeopathy and Ayurveda are both rooted in solid philosophies of their own and are among the most popular forms of alternative medicine around today. They also have two very different origins and governing principles. Homeopathy claims that “like cures like” (i.e. that a substance causing symptoms in large doses, can be used in minute doses to treat similar symptoms). Ayurveda is based on the principle of preventing and treating illness by maintaining balance in different senses of humour in the body, and harmony between the body, mind and environment.

Fundamental to the sciences of both homoeopathy and Ayurveda is a strong belief in personalised medicine – that there is no one size fits all in treatment. To add, some remedies take time to work on the body and don’t guarantee sure-shot cures to an illness – any illness.

They also don’t have “active ingredients” and the associated benefits of a specific action that allopathic medicines do. By design, they aim to address an ailment from the roots, and as a result, take a varying amount of time to act depending on how acute or chronic the ailment is. Often, they require other prescribed lifestyle changes alongside treatment to improve their quality of life.

We can – and should – expect the same rigorous standards for clinical trials and regulations in alternative medicine as we do conventional ones. Experts say that a serious shortcoming in the veracity of AYUSH research is the lack of digitised manuscripts, so researchers can authenticate their findings based on original sources.

This, along with the stronger regulation of AYUSH medicines and higher standards for practitioners of these fields could give Ayurveda and homoeopathy a fighting chance at breaking unfounded stereotypes and appealing to a wider range of people as a true, viable alternative to conventional medicine.

from Firstpost Tech Latest News https://ift.tt/2BfLUHl